RecruitingPhase 3NCT06474039

The Efficacy of Fluticasone Furoate/Vilanterol/Umeclidinium Compared With Vilanterol/Umeclidinium in Reducing Air Trapping and Airway and Blood Cytokine Levels in COPD

Sponsor

Mahidol University

Enrollment

50 participants

Start Date

Oct 1, 2024

Study Type

INTERVENTIONAL

Conditions

COPD

Summary

This study aims to demonstrate the effects of triple therapy (ICS/LABA/LAMA) and dual bronchodilators (LAMA/LABA) on air trapping in the lungs' COPD patients and inflammatory mediators

Eligibility

Min Age: 40 YearsMax Age: 80 Years

Inclusion Criteria3

Patients who have met the criteria for COPD GOLD B defined by an exacerbation not more than 1 time in the last year prior to the study enrollment. These patients will be recruited in sequential sequence.
Patients with COPD GOLD B are previously treated with either LAMA or LAMA/LABA or short-acting bronchodilators
Patients who are able to provide informed consent.

Exclusion Criteria4

\- Concomitant with active and old pulmonary TB, lung cancer, bronchiectasis, lung fibrosis, destroyed lung, other malignancy, active heart diseases.
Receiving long-term treatment with immunosuppressive drugs and systemic corticosteroids
Being treated with triple therapy (ICS/LABA/LAMA)
Being in terminally ill conditions